ROS1 and non-small cell lung carcinoma: Comutations reported at baseline are shown in Fig. 3 (n = 54); the prevalence of comutations identified by liquid biopsies in BFAST Cohort D was comparable to that identified by tissue-based testing from the FMCore database (patients with NSCLC in the FMCore database with ROS1 rearrangement, n = 612; Extended Data Fig. 3)30.